Tafasitamab
Tafasitamab
Definition
An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities.Tafasitamab targets and binds to CD19, thereby depleting and eliminating CD19-expressing B-cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.
Also known as Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR 00208, MOR 208, MOR-00208, MOR-208, MOR00208, MOR208, TAFASITAMAB, Tafasitamab-cxix, XmAb-5574, XmAb5574 — per NCIT
Also identified as
- ATC L01FX12 per RXNORM
- NCIT NCIT:C95768 per NCIT
- SCTID 896700009 per RXNORM
- SCTID 896714009 per RXNORM
- UNII QQA9MLH692 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Diffuse large B-cell lymphoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Lymphoid system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.